<DOC>
	<DOCNO>NCT03020004</DOCNO>
	<brief_summary>The purpose study evaluate Efficacy , Safety Pharmacokinetics Ritonavir-boosted Danoprevir ( ASC08 ) Combination Peg-IFN RBV Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1 .</brief_summary>
	<brief_title>Efficacy Safety Danoprevir/r + PR 12-week Triple Therapy Treatment-Naive , Non-Cirrhotic , G1 CHC China II</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>Willing able provide write informed consent Chronic HCV infection ( ≥ 6 month ) ; Positive HCV antibody Serum HCV RNA ≥ 1 × 104 IU/mL Hepatitis C virus GT1 Never receive priortreatment HCV interferon , RBV , directacting hosttargeting antiviral HCV The liver biopsy method protocol ( noncirrhosis define : Metavir score ˂ 4 ) , determine Fibroscan define : ˂ 14.6 kPa . Patients obtain liver biopsy Fibroscan last 1 year study related Fibroscan perform order confirm diagnosis Others specify detailed protocol Patients Fibroscan detection value &gt; 12.9 kPa , histologic examination liver cirrhosis patient Presence history nonhepatitis C chronic liver disease , include limited , autoimmune hepatitis , α1antitrypsin deficiency , C282Y homozygous hemochromatosis , Wilson 's disease , drug toxininduced liver disease , alcoholrelated liver disease , primary biliary cirrhosis , sclerosing cholangitis , porphyria cutanea tarda cause liver pathology require phlebotomy Patients history liver cell cancer , screen screen suspect hepatocellular carcinoma ( HCC ) patient , image study find suspicious nodule , AFP &gt; 50 ng/mL Positive hepatitis A antibody，positive hepatitis B surface antigen，syphilis antibody HIV antibody screen Others specify detailed protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Danoprevir</keyword>
	<keyword>SVR12</keyword>
	<keyword>Chinese HCV G1</keyword>
	<keyword>non-cirrhotic</keyword>
</DOC>